Saxenda injection dose for weight loss: the facts, clearly

The biggest misconception: higher dose, faster results

The most persistent myth about Saxenda's dose schedule is that starting at the highest dose will produce quicker results. It will not, and clinicians are clear on why. Liraglutide causes gastrointestinal side effects, particularly nausea, vomiting and diarrhoea, that can be severe if the body is not given time to adjust. The escalation schedule exists to reduce that risk, not to delay treatment. Starting at 0.6mg for a full week before moving to 1.2mg, then 1.8mg, then 2.4mg, and finally 3mg, is the structure set out in the prescribing information precisely because tolerability drives adherence, and adherence drives outcomes. Jumping ahead rarely speeds up weight loss; it more often ends treatment early.

The 3mg dose is the only dose shown in clinical trials to produce meaningful weight loss. Sub-therapeutic doses used during the titration period are a preparation phase, not a treatment phase. Patients who do not reach 3mg and stay there are unlikely to see the results the trial evidence describes. That is a practical point worth understanding before starting any programme, and our guide to the 2.5 weight loss injection explains how intermediate dose steps work in practice across comparable programmes. The full guide to weight-loss injection dose schedules covers how this compares across available medicines.

What the trial evidence says about Saxenda's effectiveness at 3mg

The pivotal SCALE Obesity and Prediabetes trial, published in The Lancet, followed adults using liraglutide 3mg alongside lifestyle changes for 56 weeks. Participants lost an average of around 8% of their body weight, compared with roughly 2.6% on placebo. Approximately 63% lost at least 5% of body weight, and around 33% lost at least 10%. Those are meaningful results for many people. They are also lower than the average losses reported in more recent trials of once-weekly semaglutide and tirzepatide, which is relevant context when choosing a medicine, though that choice belongs with a prescriber, not a website.

The NHS guidance on obesity treatment notes that weight-loss medicines work best alongside a reduced-calorie diet and regular physical activity, and it is also worth understanding how supportive treatments such as vitamin B12 injections are dosed and timed alongside a weight loss programme. Saxenda is no exception. The 8% average figure from SCALE came from participants who also made lifestyle changes; the medicine alone, in isolation from diet and movement, is not how these trials were designed. If 5% or more weight loss has not occurred by week 12 on the full 3mg dose, the prescribing guidance recommends reassessing whether treatment should continue.

Saxenda is not the only option, and for most people starting today, it is not the first one either

This matters practically. Saxenda received its UK licence for weight management before semaglutide and tirzepatide were approved for the same indication. Since then, NICE has recommended both Wegovy (semaglutide, TA875) and Mounjaro (tirzepatide) for weight management under specific criteria, and both have produced larger average weight reductions in head-to-head or comparative trial contexts. Saxenda's daily injection schedule is also a practical consideration, many patients find a once-weekly pen considerably easier to build into a routine.

nume does not currently dispense Saxenda for weight loss. The weight-loss treatment overview sets out what is available: Wegovy and Mounjaro, both once-weekly injections, and the Wegovy tablet, approved by the MHRA in June 2026 as the UK's first oral GLP-1 medicine for weight management. If you are considering switching from Saxenda or wondering whether one of these medicines might suit you better, the right starting point is a clinical consultation. A prescriber who can review your full history is the person to make that call.

A note on Saxenda, side effects and what to watch for

The side-effect profile for Saxenda overlaps significantly with other GLP-1 medicines. Nausea is the most commonly reported, especially in the first few weeks of each dose increase. Vomiting, constipation, diarrhoea and stomach pain also feature. Most people find these symptoms settle, often within a couple of weeks of stabilising on a dose. The titration schedule described above is partly designed to give the body that settling time.

More serious but less common effects include gallbladder problems and, rarely, pancreatitis. The MHRA has highlighted acute pancreatitis as a known risk across GLP-1 medicines: persistent, severe stomach pain that radiates towards the back, with or without vomiting, warrants prompt medical attention. Suspected side effects from any medicine can be reported directly through the Yellow Card scheme. If you are already on a GLP-1 medicine and have questions about side effects, our team is available seven days a week, see the contact page for how to reach us, or browse the FAQs for answers to the questions we hear most often.

For anyone currently researching how to access weight-loss injections in the UK, it is worth knowing that all of these medicines are prescription-only and require a clinical assessment before any dose (starter or otherwise) can be issued, and the same principle applies to adjunct treatments such as those covered in our guide to l-carnitine injection dosage for weight loss. That is not a bureaucratic hurdle; it is how safe prescribing works. When you are ready, checking your eligibility with our prescribers is a straightforward, free first step.